1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(14):974–84. doi: 10.1056/NEJM199810013391407
2. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634–57. doi: 10.1093/annonc/mdy192
3. Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline [American Society of Clinical Oncology guideline]. J Clin Oncol. 2016;34(25):3069–103. doi: 10.1200/JCO.2016.67.1487
4. Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T et al. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Breast Cancer. 2020;27(5):973–81. doi: 10.1007/s12282-020-01095-y
5. Cella DF. Measuring quality of life in palliative care. Semin Oncol. 1995;22(Suppl 3):73–81
6. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622–9. doi: 10.7326/0003-4819-118-8-199304150-00009
7. King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):171–84. doi: 10.1586/erp.11.9
8. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9. doi: 10.1016/j.jclinepi.2007.03.012
9. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44. doi:10.1200/JCO.1998.16.1.139
10. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004;57(9):898–910. doi: 10.1016/j.jclinepi.2004.01.012
11. Musoro JZ, Coens C, Fiteni F, Katarzyna P, Cardoso F, Russell NS et al., & EORTC Breast and Quality of Life Groups. Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer. J.N.C.I. Cancer Spec. 2019;3(3):pkz037. doi: 10.1093/jncics/pkz037
12. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999;55(2):189–99. doi: 10.1023/a:1006263818115
13. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997;15(3):974–86. doi: 10.1200/JCO.1997.15.3.974
14. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9. doi: 10.1200/JCO.1993.11.3.570
15. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11(3):207–21. doi: 10.1023/a:1015276414526
16. Burris HA, 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013;119(10):1908–15. doi: 10.1002/cncr.28010
17. Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–8. doi: 10.1200/JCO.2016.67.3061
18. Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–54. doi: 10.1093/annonc/mdw139
19. Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J et al. Health-related quality of life from the Falcon phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer. 2018;94:206–15. doi: 10.1016/j.ejca.2018.02.026
20. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600. doi: 10.1200/JCO.2010.28.8415
21. Ringash J, O’Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110(1):196–202. doi: 10.1002/cncr.22799